Skip to content

Spinal Stimulation and Mobility Devices

Transcutaneous Stimulation and Mobility Device Use for Individuals With Neurologic Conditions

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05520359
Enrollment
20
Registered
2022-08-29
Start date
2022-08-04
Completion date
2026-12-31
Last updated
2025-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral Palsy, Hypoxic-Ischemic Encephalopathy, Periventricular Leukomalacia, Premature Birth, Stroke

Keywords

Pediatric, Mobility Aids, Assistive Technology, Spinal Stimulation

Brief summary

This research study will combine non-invasive spinal stimulation with mobility devices to examine the acute impact of the individual and combined effects of these innovative techniques on mobility in children with cerebral palsy.

Detailed description

For people with neurological conditions, excessive and inappropriate muscle activity resulting from injured sensory pathways (e.g., spasticity or hypertonicity) contributes to inefficient movement, bone deformities, pain, and other comorbidities. Research with humans and animals have highlighted the critical importance of both motor and sensory pathways for motor learning after neurologic injury. However, the best techniques for engaging motor and sensory pathways in a way that brings high quality mobility are not well understood. With this study we will examinee how increased sensory feedback, through mobility device use and electrical spinal stimulation, impact movement mechanics in people with neurological conditions to inform long-term studies and eventual implementation into clinical practice. Mobility devices offer a promising approach to improve mobility rehabilitation through engagement of sensory and motor pathways. These devices can either assist in movement by providing support to perform an activity or they can be used to provide resistance to build strength. Mechanistically how these devices impact movement mechanics is still not well understood. Electrical spinal stimulation with intensive, repetitive training has demonstrated exciting potential to improve limb function after neurologic injury. Spinal stimulation has shown to improve motor function with long-term training. Stimulation is hypothesized to improve motor pathways through boosting sensory input. However, the neuromechanical effects of stimulation as a result of increased sensory feedback over an acute time frame has not been explored in efforts to test this hypothesis. This study aims to evaluate the acute effects of increased afferent feedback in individuals with neurological conditions via mobility devices and spinal stimulation. Understanding how these approaches affect the quantity and quality of movement in the short term is a first step before determining potential treatment outcomes. In this research, we will quantify the neuromechanics of movement with and without these approaches for individuals with neurologic disorders.

Interventions

DEVICEMobility Device

Use of mobility device during session.

A stimulator will be used non-invasively stimulate the spine at the neck and/or lower back (cervical and/or lum

Sponsors

Seattle Children's Hospital
CollaboratorOTHER
University of Washington
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Intervention model description

Randomized order of visits with individual and combined effects of mobility devices and spinal stimulation.

Eligibility

Sex/Gender
ALL
Age
4 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* have a neurologic condition * are 4-70 years of age * have stable medical condition * can perform simple cued motor tasks and who can follow 2-3 step commands * who are volunteering to be involved in this study * can provide feedback on comfort and experience during lab visits

Exclusion criteria

* have significant medical disease; including uncontrolled systemic hypertension with values above 170/100 mmHg; cardiac or pulmonary disease; uncorrected coagulation abnormalities or need for therapeutic anticoagulation. * have cardiovascular or musculoskeletal disease or injury that would prevent full participation in physical therapy intervention * have a history of uncontrolled seizures * have unhealed fracture or other musculoskeletal impairment that might interfere with lower extremity rehabilitation or testing activities * are dependent on ventilation support * have implanted stimulator (e.g. epidural stimulator, vagus nerve stimulator, pacemaker, cochlear implant, etc) or drug delivery device (e.g. baclofen pump) * have history of orthopedic surgery in lower extremities or neurosurgery that may be a confounding factor for interpretation of the results (such as tendon transfer, tendon or muscle lengthening for spasticity management, injection therapies to lower extremity muscles, etc.) in last 12 months * have established osteoporosis and taking medication for osteoporosis treatment. * have rheumatic diseases (rheumatoid arthritis, systemic lupus erythematosus, etc.) * have active cancer

Design outcomes

Primary

MeasureTime frameDescription
Muscle CoordinationComparing first and last minute of walking on treadmill at each experimental session.Change in level of co-contraction between the plantarflexor and tibialis anterior muscles during the gait cycle monitored from electromyography recordings.

Secondary

MeasureTime frameDescription
Modified Ashworth ScalePhysical exam conducted at the beginning and end of each experimental session.Change in summed score of spasticity from lower-extremity muscles. Lower values indicate less spasticity.
Plantarflexor Muscle StrengthPhysical exam conducted at the beginning and end of experimental session.Change in maximum voluntary contraction level of the plantarflexor muscles taken as the average of three trials where the participant exerts the maximum amount of force measured from a handheld dynamometer with verbal encouragement.

Countries

United States

Contacts

Primary ContactKatherine Steele, PHD
kmsteele@uw.edu206-685-2390
Backup ContactKatie Landwehr, MS
klandweh@uw.edu937-231-1205

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026